International Flavors & Fragrances (IFF) Consumer Analyst Group of New York Conference 2025 summary

Strategic overview and financial performance

• Achieved $11.5 billion in 2024 sales and $2.2 billion EBITDA, with a 19–19.2% margin and strong recovery from prior lows.

• 2024 saw 6% top-line growth, 16% EBITDA growth, and 210 basis points of margin expansion, driven by volume recovery and operational improvements.

• 2025 outlook projects $10.6B–$10.9B revenue, $2.0B–$2.15B EBITDA, 1–4% volume growth, and 5–10% EBITDA growth, with continued reinvestment for sustainable growth.

• Capital allocation focuses on increased CapEx (6% of sales), maintaining dividends, reducing leverage below 3x net debt/EBITDA by Q2 2025, and potential share buybacks once targets are met.

• Completed Cosmetics Ingredients divestiture and announced Pharma Solutions sale, with ongoing portfolio optimization to enhance strategic fit and returns.

Innovation, R&D, and business model transformation

• Invests $671 million annually in R&D (5.8% of sales), supporting 3,400 R&D employees, 8,000+ patents, and 50+ research centers globally.

• Biotech capabilities, especially in Health & Biosciences, are leveraged across all business units for differentiation and growth.

• Business units have end-to-end accountability, empowered leadership, and tailored strategies under four pillars: people, customer, innovation, and operational excellence.

• Digital transformation and AI are being deployed to drive efficiency, speed, and margin improvement.

• Investment plan prioritizes high-ROIC projects in probiotics, cultures, enzymes, and transformative growth areas like DEB manufacturing.

Health & Biosciences and biotechnology leadership

• Health & Biosciences division, built from DuPont and other science company assets, is a $2B+ business with 30% EBITDA margin and mid-single-digit growth.

• Holds 5,500+ bioscience patents and invests 9% of sales in R&D, maintaining a leading bank of microbial strains and protein sequences.

• Core technologies include enzymes, probiotics, and live cultures, with a focus on discovery, scaling, and application expertise.

• Recent innovations include TexStar (sugar-to-fiber enzyme), next-gen anaerobic probiotics, and biodegradable high-performance polymers.

• Bioscience assets enable sustainable manufacturing, cost reduction, and alignment with health, wellness, and sustainability megatrends.